Breaking News Instant updates and real-time market news.

A

Agilent

$69.32

(0.00%)

, TMO

Thermo Fisher

$196.52

(0.00%)

09:32
01/04/18
01/04
09:32
01/04/18
09:32

Barclays life science tools analysts hold an analyst/industry conference call

Life Science Tools & Diagnostics Analysts provide a comprehensive update on the Life Science Tools, Diagnostics, Labs & CRO industries, including proprietary end market trackers and industry overviews on an Analyst/Industry conference call to be held on January 4 at 11 am.

A

Agilent

$69.32

(0.00%)

TMO

Thermo Fisher

$196.52

(0.00%)

HOLX

Hologic

$43.49

0.62 (1.45%)

QGEN

Qiagen

$31.93

0.57 (1.82%)

QDEL

Quidel

$44.91

0.48 (1.08%)

LH

LabCorp

$163.05

(0.00%)

IQV

Iqvia

$99.52

(0.00%)

PRAH

PRA Health

$90.44

-0.35 (-0.39%)

CRL

Charles River

$110.31

(0.00%)

ICLR

Icon

$114.02

-0.46 (-0.40%)

INCR

Ticker changed to SYNH

$43.80

-0.3 (-0.68%)

ILMN

Illumina

$230.32

6.29 (2.81%)

MYGN

Myriad Genetics

$35.10

0.19 (0.54%)

DGX

Quest Diagnostics

$99.25

(0.00%)

WAT

Waters

$197.77

(0.00%)

GHDX

Genomic Health

$34.04

-0.51 (-1.48%)

PKI

PerkinElmer

$76.16

(0.00%)

  • 04

    Jan

  • 09

    Jan

  • 23

    Jan

  • 25

    Jan

  • 08

    Feb

  • 16

    Feb

  • 26

    Feb

A Agilent
$69.32

(0.00%)

11/14/17
MSCO
11/14/17
NO CHANGE
Target $88
MSCO
Overweight
Agilent price target upped to $88 on above consensus estimates at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw believes share gains and a strong macro environment can drive another year of 5% organic growth for Agilent and he notes that his EPS estimates are higher than consensus in 2018 and well above consensus in 2019. The analyst, who also sees more room for margin expansion at Agilent, raised his price target on the shares to $88 from $86 and maintains an Overweight rating on the shares.
11/21/17
JPMS
11/21/17
NO CHANGE
Target $75
JPMS
Overweight
Agilent price target raised to $75 from $70 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Agilent Technologies to $75 saying the company's outlook again looks conservative. He expects fiscal 2018 to be "another solid year of beat and raise quarters on both the top and bottom-line." The analyst keeps an Overweight rating on Agilent.
11/21/17
DBAB
11/21/17
NO CHANGE
Target $75
DBAB
Buy
Agilent selloff a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Dan Leonard recommends using the selloff in shares of Agilent Technologies from the company's weaker than expected outlook as a buying opportunity. He believes management's outlook reflects conservatism and points out Agilent saw broad-based strength in chemical and energy end markets in Q4. He trimmed his price target for the shares to $75 from $76 and keeps a Buy rating on Agilent.
01/03/18
EVER
01/03/18
INITIATION
Target $75
EVER
Outperform
Agilent initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Agilent with an Outperform and $75 price target.
TMO Thermo Fisher
$196.52

(0.00%)

01/03/18
EVER
01/03/18
INITIATION
Target $220
EVER
Outperform
Thermo Fisher initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Thermo Fisher with an Outperform and $220 price target.
12/20/17
COWN
12/20/17
NO CHANGE
COWN
Tax bill not a significant tailwind for Life Science Tool sector, says Cowen
Cowen analyst Doug Schenkel said 2017 was a good year for the Life Science Tool sector as the group outperformed the market. He believes 2018 will be tougher and said the tax bill will not be a significant tailwind for the group as many of the companies have already optimized reported tax rates and are paying an effective rate less than 20%. The analyst believes Hologic (HOLX) will benefit more than others and his top picks in the group are Exact Sciences (EXAS), Insulet (PODD), Hologic (HOLX), Thermo Fisher (TMO), and Illumina (ILMN).
11/20/17
11/20/17
NO CHANGE

Amazon disruption of healthcare 'a foregone conclusion,' says Morgan Stanley
Morgan Stanley's U.S. Internet and Healthcare teams collaborated on a report exploring Amazon's (AMZN) entry into healthcare, stating that it will likely take time but that the e-commerce giant's "disruption of healthcare is a foregone conclusion." While retail plays to Amazon's strengths with the highest profits and lowest barriers to entry, retailers like CVS (CVS) and Walgreens (WBA) have the most opportunities to adjust their business models and lower costs to defend against Amazon, the teams tell investors. Medical supply and Life Sciences distribution are "less rich" targets, but look like "low-hanging fruit," the analysts added. Cardinal Health (CAH) has the most exposure via its medical supply distribution segment, said the firm, which downgraded Cardinal to Underweight from Equal Weight, as previously reported. McKesson (MCK) also has some, but less, risk and AmerisourceBergen (ABC), which doesn't distribute medical supplies, remains immune in the near-term, the firm concluded. Others in healthcare distribution facing the most share and/or margin risk from Amazon include Thermo Fisher (TMO), Henry Schein (HSIC) and Patterson (PDCO), the firm added.
12/04/17
LEER
12/04/17
NO CHANGE
Target $200
LEER
Outperform
Thermo Fisher price target lowered to $200 from $216 at Leerink
Leerink analyst Puneet Souda lowered his price target for Thermo Fisher to $200 from $216 as he gets cautious on risk to its Lab Products and Services business. The analyst reiterates an Outperform rating on the shares.
HOLX Hologic
$43.49

0.62 (1.45%)

01/04/18
BOFA
01/04/18
UPGRADE
Target $50
BOFA
Buy
Hologic upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded Hologic (HOLX) to Buy from Neutral and increased its price target to $50 from $42. The analyst was cautious on Hologic's acquisition of CynoSure (CYNO) last February and still sees risk in Q1, but said comps get easier for the rest of FY18 and expects shares to move higher if CynoSure rebounds. Further, the analyst said Hologic's core business is solid with potential upside, sees benefits from tax reform, views valuation as attractive, and expects the multiple to trend back to Med Tech peer levels.
01/03/18
EVER
01/03/18
INITIATION
Target $50
EVER
Outperform
Hologic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Hologic with an Outperform rating and $50 price target. The analyst believes management can turnaround the business and finds expectations low at at current share levels.
01/03/18
ADAM
01/03/18
NO CHANGE
ADAM
Canaccord names Illumina among top 2018 picks in Diagnostics and Tools industry
Canaccord analyst Mark Massaro rolled out his top 2018 picks in the Diagnostics and Tools segment after noting his 2017 picks returned 38% overall. He said he prefers larger companies in 2018 and said Illumina (ILMN) is a must own here due to its continued market dominance. The analyst raised his price target to $255 from $235 on Illumina shares. The analyst also recommends Exact Sciences (EXAS) as he expects its strong growth to continue. Massaro reiterated his $60 price target on Exact Sciences shares. He also likes Hologic (HOLX) and expects 2018 to be a bounce back year, raising his price target to $50 from $44. The analyst also likes Lab Corp. (LH) and believes it is likely to see an earnings acceleration and multiple expansion. He raised his price target to $190 from $175 on Lab Corp. shares. Finally, Massaro likes IDEXX (IDXX) for its new product launches and underlying global trends, keeping a $180 price target on the shares.
12/27/17
GSCO
12/27/17
NO CHANGE
GSCO
Conviction Buy
Hologic positioned to outperform in 2018, says Goldman Sachs
Goldman analyst Isaac Ro believes Conviction Buy rated Hologic is well positioned to outperform the peer group in 2018 following 2017 underperformance. The analyst sees renewed management focus and stability, which should have a positive impact on the business and investor sentiment. Ro thinks Cynosure expectations have been sufficiently reset following the most recent earnings call and the core business should see a modest boost from product cycles and tax reform.
QGEN Qiagen
$31.93

0.57 (1.82%)

01/03/18
EVER
01/03/18
INITIATION
Target $35
EVER
Outperform
Qiagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Qiagen with an Outperform rating and $35 price target.
QDEL Quidel
$44.91

0.48 (1.08%)

12/21/17
ADAM
12/21/17
NO CHANGE
Target $52
ADAM
Buy
Quidel price target raised to $52 from $48 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Quidel (QDEL) to $52 from $48 following the company's conference call to discuss its recently acquired Triage and BNP assets from Alere (ALR). The analyst believes Quidel shares are undervalued as he believes management's estimates on synergies may prove conservative, particularly because savings are likely to continue after the end of 2018. Massaro reiterated his Buy rating on Quidel shares.
12/14/17
PIPR
12/14/17
NO CHANGE
Target $50
PIPR
Overweight
Quidel may be in asset sale talks with Beckman, says Piper Jaffray
At 12 times EBITDA, shares of Quidel are a "good value," Piper Jaffray analyst William Quirk tells investors in a research note. The analyst believes Beckman's latest legal move has opened the door to a potential asset sale. Beckman filed a brief on Tuesday permitting Quidel additional time to reply to its initial legal filing, the analyst points out. He believes this may have been done because of the possibility that the two companies are in discussions around a BNP asset sale. Quirk thinks that if Quidel can get above $700M pre-tax from a sale of its BNP assets, it would essentially double its EBITDA for free. The analyst keeps an Overweight rating on Quidel with a $50 price target.
01/02/18
ADAM
01/02/18
NO CHANGE
Target $52
ADAM
Buy
Quidel remains undervalued at current levels, says Canaccord
Canaccord analyst Mark Massaro said he believes Quidel shares remain undervalued at current levels. He believes the company remains poised to benefit from a near-record start to the flu season, the synergies from its recent acquisitions and U.S. tax reform. Massaro reiterated his Buy rating and $52 price target on Quidel shares.
01/04/18
KING
01/04/18
UPGRADE
Target $52
KING
Buy
Quidel upgraded to Buy, named a Best Idea for 2018 at CL King
CL King upgraded Quidel to Buy from Neutral and named its a Best Idea for 2018 citing "compelling valuation" on post integration numbers. Analyst David Westenberg established a $52 price target on Quidel shares saying it trades at a "massive discount" to its diagnostic peers and said upside to the stock remains a strong flu season, a BNP buyout and market realization of value.
LH LabCorp
$163.05

(0.00%)

10/12/17
WELS
10/12/17
UPGRADE
Target $175
WELS
Outperform
LabCorp resumed with an Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans resumed coverage of LabCorp and upgraded the shares to Outperform with a $175 price target. The analyst sees LabCorp outperforming Quest Diagnostics (DGX) due to its "slightly" higher revenue growth profile and diversification as well as more attractive valuation.
10/26/17
CHLM
10/26/17
NO CHANGE
Target $180
CHLM
Buy
LabCorp price target raised to $180 from $175 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for LabCorp to $180 from $175 following a better than expected Q3 driven by "solid" organic volume growth. The analyst reiterates a Buy rating on the shares.
09/25/17
ADAM
09/25/17
NO CHANGE
ADAM
Genomic Health, Vermillion among 'few winners' after PAMA news, says Canaccord
After the CMS released the proposed 2018 draft Medicare reimbursement rates for clinical lab tests under the Protecting Access to Medicare Act, or PAMA, which marks a major overhaul of Medicare reimbursement for tests, Canaccord analyst Mark Massaro said the cuts were greater than he expected. He identifies the "losers" after the news as LabCorp (LH), Quest Diagnostics (DGX) and GenMark (GNMK) while he sees Genomic Health (GHDX), VeraCyte (VCYT) and Vermillion (VRML) as among the "few winners."
IQV Iqvia
$99.52

(0.00%)

11/13/17
KEYB
11/13/17
DOWNGRADE
KEYB
Sector Weight
QuintilesIMS downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Donald Hooker downgraded QuintilesIMS (Q), which will be changing its name on Wednesday to IQVIA (IQV), to Sector Weight citing valuation. The analyst notes the shares are trading at over 14 times 2018 EBITDA estimates.
12/14/17
MUFG
12/14/17
INITIATION
Target $112
MUFG
Neutral
Iqvia initiated with a Neutral at MUFG
MUFG analyst Jason Twizell started Iqvia with a Neutral rating and $112 price target.
11/09/17
MZHO
11/09/17
DOWNGRADE
Target $108
MZHO
Neutral
IQVIA downgraded to Neutral from Buy at Mizuho
Mizuho analyst Ann Hynes downgraded IQVIA to Neutral citing valuation and raised her price target on shares to $108.
PRAH PRA Health
$90.44

-0.35 (-0.39%)

12/11/17
LEHM
12/11/17
INITIATION
Target $94
LEHM
Overweight
PRA Health initiated with an Overweight at Barclays
Barclays analyst Jack Meehan started PRA Health Sciences with an Overweight rating and $94 price target. The analyst views the stock's valuation as attractive in the context of the company's "market-leading growth rates." He believes the integration of data into clinical trials is going to become a "need to have."
10/30/17
KEYB
10/30/17
NO CHANGE
Target $93
KEYB
Overweight
PRA Health price target raised to $93 from $86 at KeyBanc
KeyBanc analyst Donald Hooker raised his price target for PRA Health to $93 from $86 to reflect the stronger than expected trends at Symphony Health and over 15% EBITDA growth in 2018 and 2019. The analyst reiterates an Overweight rating on the shares.
10/16/17
FBCO
10/16/17
NO CHANGE
Target $90
FBCO
Outperform
PRA Health price target raised to $90 from $84 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for PRA Health to $90 from $84 on the latest evidence of strengthening fundamentals as it relates to the biotechnology funding environment. The analyst reiterates an Outperform rating on the shares.
12/14/17
MUFG
12/14/17
INITIATION
Target $102
MUFG
Overweight
PRA Health initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started PRA Health with an Overweight rating and $102 price target. The analyst finds the company's premium valuation justified given its high-teens percentage revenue growth outlook and "consistent" execution.
CRL Charles River
$110.31

(0.00%)

10/09/17
JEFF
10/09/17
UPGRADE
Target $69
JEFF
Buy
INC Research upgraded to Buy from Hold at Jefferies
Jefferies analyst David Windley upgraded INC Research (INCR) to Buy saying the recent share pullback provides a "compelling" entry point. The analyst sees a more competitive clinical contract research organization post the inVentiv merger. He raised his price target for the shares to $69. Windley also raised his price target for Buy-rated Charles River Laboratories to $130 and for Buy-rated Icon plc (ICLR) to $132. The analyst believes the CRO will accelerate in 2018 to 6.5% from 5.6% in 2017.
12/13/17
ARGS
12/13/17
INITIATION
Target $120
ARGS
Buy
Charles River initiated with a Buy at Argus
Argus analysts John Eade and Anne Petrino initiated Charles River with a Buy and $120 price target. The analysts said shares have underperformed over the past quarter due to an impairment charges related to a facility closure. They believe the closure will result in 2018 savings and note fundamentals are stable and the company is expanding through acquisition and partnerships.
10/16/17
FBCO
10/16/17
NO CHANGE
Target $112
FBCO
Neutral
Charles River price target raised to $112 from $95 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Charles River to $112 from $95 on the latest evidence of robust fundamentals as it relates to the biotechnology funding environment, strengthening her conviction in its near-term prospects. The analyst reiterates a Neutral rating on the shares.
12/13/17
12/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lowe's (LOW) initiated with a Buy at Guggenheim. 2. Aimmune (AIMT) initiated with an Overweight at Cantor Fitzgerald. 3. Westlake Chemical (WLK) reinstated with a Buy at Deutsche Bank. 4. Wabtec (WAB) initiated with an Outperform at Cowen. 5. Charles River (CRL) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ICLR Icon
$114.02

-0.46 (-0.40%)

10/30/17
RHCO
10/30/17
NO CHANGE
Target $138
RHCO
Buy
Icon price target raised to $138 from $126 at SunTrust
SunTrust analyst Sandy Draper raised his price target on ICON Plc to $138 and kept his Buy rating following Q3 results. Draper says he is boosting his estimates and target multiple given that the revenue fall-off from Pfizer - its biggest client - was not as pronounced as expected, while the company was also able to reduce its SG&A expenses.
11/13/17
KEYB
11/13/17
NO CHANGE
Target $125
KEYB
Overweight
Icon price target raised to $125 from $115 at KeyBanc
KeyBanc analyst Donald Hooker raised his price target for Icon to $125 from $115 on valuation following quarterly results. The analyst reiterates an Overweight rating on the shares.
10/16/17
FBCO
10/16/17
NO CHANGE
Target $120
FBCO
Outperform
Icon price target raised to $120 from $105 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Icon to $120 from $105 on the latest evidence of strengthening fundamentals as it relates to the biotechnology funding environment. The analyst reiterates an Outperform rating on the shares.
10/18/17
GSCO
10/18/17
NO CHANGE
Target $124
GSCO
Conviction Buy
Icon remains a top pick into Q3 at Goldman Sachs
Goldman analyst Robert Jones said Icon remains a top pick into Q3 as he believes there is support from recent M&A and strong non-Pfizer booking to achieve second half estimates. Jones is above consensus for 2018 and expects Icon to provide an early positive read on 2018. The analyst rates Icon a Conviction Buy with a $124 price target.
INCR Ticker changed to SYNH
$43.80

-0.3 (-0.68%)

12/11/17
LEHM
12/11/17
INITIATION
Target $40
LEHM
Equal Weight
INC Research initiated with an Equal Weight at Barclays
Barclays analyst Jack Meehan started INC Research with an Equal Weight rating and $40 price target. The analyst believes the leverage of the combined INC Research/inVentiv company "magnifies downside risk" for equity holders if execution is worse than expected.
12/20/17
BARD
12/20/17
NO CHANGE
Target $50
BARD
Outperform
INC Research recovery trade still has upside, says Baird
Baird analyst Eric Coldwell noted INC Research shares have recovered 25% from their recent lows, but he believes they still have room to run. He said fundamental confidence is increasing, driven by proprietary analysis and competitor checks. The analyst said his sum-of-the-parts valuation implies the Commercial segment multiple remains depressed and he would be an aggressive near-term buyers up to $46 a share. Coldwell reiterated his Outperform rating and raised his price target to $50 from $46 on INC Research shares.
12/11/17
JEFF
12/11/17
NO CHANGE
Target $55
JEFF
Buy
INC Research not as bad as Q3 call suggests, says Jefferies
Jefferies analyst David Windley believes the prospects at INC Research are not as bad as the Q3 call suggested. The company's initial 2018 outlook for mid-single-digit Clinical growth is highly conservative, Windley tells investors in a research note. He sees INC's margins expanding in 2018 and keeps a Buy rating on the stock with a $55 price target.
12/01/17
RHCO
12/01/17
NO CHANGE
Target $50
RHCO
INC Research price target lowered to $50 from $67 at SunTrust
SunTrust analyst Sandy Draper lowered his price target on INC Research to $50 to reflect the selloff in stock price over the past three weeks that followed disappointing Q3 earnings. Draper keeps his Buy rating, saying that long-term growth outlook does not appear impaired, with bookings growth and new drug approval prospects being stronger today than they were in the prior quarter or a year ago.
ILMN Illumina
$230.32

6.29 (2.81%)

01/03/18
EVER
01/03/18
INITIATION
Target $250
EVER
Outperform
Illumina initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Illumina with an Outperform and $250 price target.
01/02/18
01/02/18
UPGRADE
Target $250

Outperform
Illumina upgraded to Outperform at Wells Fargo
As previously reported, Wells Fargo analyst Tim Evans upgraded Illumina to Outperform from Market Perform saying he is more positive on growth fundamentals as 2018 is likely to resolve key debates about capacity utilization and demand elasticity in a bullish direction. The analyst also raised his price target on the shares to $250 from $205.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $274
PIPR
Overweight
Illumina price target raised to $274 from $228 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Illumina to $274 citing his positive channel checks in Q4. His checks found 57 NovaSeq installs during Q4, compared to his 95 modeled estimate. The analyst notes that Illumina placed 90 NovaSeqs during Q3 after his checks found 50. Quirk sees see potential upside driven by the array business and keeps an Overweight rating on Illumina shares.
MYGN Myriad Genetics
$35.10

0.19 (0.54%)

11/10/17
JPMS
11/10/17
NO CHANGE
Target $19
JPMS
Underweight
JPMorgan continues to see downside risk in Myriad Genetics
After conducting a survey of high-volume, U.S.-based psychiatrists to get a better sense of the traction GeneSight test is seeing and the longer term market opportunity, JPMorgan analyst Tycho Peterson continues to see risk to the downside in Myriad Genetics shares. Responses overall were mixed, with some indicating GeneSight provides meaningful clinical information while others were cautious on the utility of the test, Peterson tells investors in a research note. The analyst believes the failure of the GeneSight clinical utility study to hit the primary endpoint increases questions on Myriad's ability to gain meaningful incremental reimbursement. He keeps an Underweight rating on the shares with a $19 price target.
09/22/17
SPHN
09/22/17
NO CHANGE
Target $40
SPHN
Overweight
Myriad Genetics price target raised to $40 from $36 at Stephens
Stephens analyst Drew Jones said that after the firm hosted a series of panels with healthcare industry professionals, he believes Myriad Genetics is well positioned to benefit from two key themes that came to the forefront - limiting risk and reducing cost. Jones, who noted that genetic testing was cited repeatedly as a potential lever for cost savings, reiterates his Overweight rating on Myriad and raised his price target on the stock to $40 from $36.
11/02/17
PIPR
11/02/17
NO CHANGE
PIPR
Neutral
Myriad trial hit two important secondary endpoints, says Piper Jaffray
Piper Jaffray analyst William Quirk notes shares of Myriad Genetics are sinking after its key growth asset GeneSight missed the primary endpoint from a large, double blind clinical trial. The study, though, hit two important secondary endpoints that may have a positive impact on longer-term private payer coverage, Quirk tells investors in a research note. The analyst believes the secondary endpoints "may prove to be more important for driving future revenue growth." He keeps a Neutral rating on shares of Myriad Genetics.
12/11/17
PIPR
12/11/17
NO CHANGE
PIPR
Overweight
Piper says CMS coding edits could negatively impact Myriad Genetics
The Centers for Medicare and Medicaid Services made an edit to its procedure guidelines, essentially stating labs should use code 81162, instead of combining 81211 and 81213, Piper Jaffray analyst William Quirk tells investors in a research note. The analyst believes Myriad Genetics bills BRCA tests using the two codes. As such, the edit by CMS could have financial implications for the company as 81162 is paid 21% lower than the combined 81211/81213 rate, Quirk points out. He notes, however, that Myriad management states these coding edits were expected and already factored into guidance. Quirk believes the company's outlook for the second half of 2018 "appears low enough," but he notes that this is the first he's heard about the CMS change. He has a Neutral rating on Myriad with a $29 price target. The stock in morning trading is down 3% to $32.66.
DGX Quest Diagnostics
$99.25

(0.00%)

10/10/17
10/10/17
DOWNGRADE
Target $113

Buy
Quest Diagnostics removed from Conviction Buy List at Goldman Sachs
As previously reported, Goldman removed Quest Diagnostics from the Conviction Buy List and lowered its price target to $113 from $121. Analyst Isaac Ro thinks share gains associated with PAMA reimbursement cuts could take time to manifest as competitors debate long-term strategies. The analyst maintains a Buy rating on Quest given its a pure-play on lab testing, margin expansion opportunities, and shareholder friendly capital deployment.
10/12/17
WELS
10/12/17
INITIATION
Target $88
WELS
Market Perform
Quest Diagnostics resumed with a Market Perform at Wells Fargo
Wells Fargo analyst Tim Evans resumed coverage of Quest Diagnostics with a Market Perform rating and $88 price target. The rating is unchanged from his firm's prior coverage.
10/17/17
CHLM
10/17/17
NO CHANGE
Target $100
CHLM
Hold
Quest Diagnostics price target lowered to $100 from $110 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich lowered his price target for Quest Diagnostics to $100 from $110 to account for hurricane-related disruption in Florida, Texas, and Puerto Rico based on its disclosure in late September. The analyst views the weather-related impact as a one-time event. He reiterates a Hold rating on the shares.
WAT Waters
$197.77

(0.00%)

12/04/17
12/04/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Buy from Hold at Deutsche Bank with analyst Amit Mehrotra saying the current valuation overly discounts the company's heightened investment cycle given its e-commerce growth opportunities. 2. Waters (WAT) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Steve Beuchaw citing the firm's October lab survey indicated that Pharma R&D budgets will accelerate in 2018 and Waters' implied market share loss in Pharma labs has moderated. 3. Globus Medical (GMED) upgraded to Outperform from Market Perform at Wells Fargo with analyst Larry Biegelsen saying he likes the company's diversification strategy amid a "weak" spine market. 4. eBay (EBAY) upgraded to Outperform from Market Perform at BMO Capital with analyst Daniel Salmon saying the current consensus for Gross Merchandise Volume are conservative, as it will likely accelerate its growth rate in 2018. 5. Owens Corning (OC) upgraded to Top Pick from Outperform at RBC Capital with analyst Robert Wetenhall saying the rating change reflects his increased confidence in fiscal 2018 outlook, projecting a double-digit EBITDA growth rate and a robust free cash flow generation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/18
EVER
01/03/18
INITIATION
Target $198
EVER
In Line
Waters initiated with an In Line at Evercore ISI
Evercore ISI analyst Ross Muken initiated Waters with an In Line and $198 price target.
12/04/17
MSCO
12/04/17
UPGRADE
MSCO
Equal Weight
Waters upgraded to Equal Weight from Underweight at Morgan Stanley
12/04/17
12/04/17
UPGRADE
Target $230

Equal Weight
Waters upgraded to Equal Weight at Morgan Stanley as share losses moderate
As previously reported, Morgan Stanley analyst Steve Beuchaw upgraded Waters to Equal Weight from Underweight after the firm's October lab survey indicated that Pharma R&D budgets will accelerate in 2018 and Waters' implied market share loss in Pharma labs has moderated. He also has updated his tax analysis to reflect the proposed elements of the House and Senate tax bills, noting that over 95% of the company's cash is held overseas and its "repatriation opportunity can no longer be overlooked." Beuchaw raised his price target on Waters shares to $230 from $207.
GHDX Genomic Health
$34.04

-0.51 (-1.48%)

09/29/17
ADAM
09/29/17
NO CHANGE
Target $40
ADAM
Buy
Genomic Health price target raised to $40 from $35 at Canaccord
Following meetings with management, Canaccord analyst Mark Massaro raised his price target on Genomic Health to $40 from $35, citing his expectations for it to achieve double digit growth and accelerate levels of profitability in 2018 and 2019. The analyst believes the shares could hit $40 in early 2018. Massaro reiterated his Buy rating on Genomic Health shares.
12/20/17
WBLR
12/20/17
DOWNGRADE
WBLR
Market Perform
Genomic Health downgraded to Market Perform from Outperform at William Blair
William Blair analyst Amanda Murphy downgraded Genomic Health to Market Perform citing valuation with the shares rallying recently on reports of a potential sale.
12/13/17
JPMS
12/13/17
DOWNGRADE
Target $25
JPMS
Underweight
Genomic Health downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Genomic Health to Underweight and cut his price target for the shares to $25 from $28. The analyst believes the company will be challenged to outgrow a maturing market for its core U.S. invasive breast business. He sees better risk/reward opportunities in other names.
PKI PerkinElmer
$76.16

(0.00%)

12/19/17
BOFA
12/19/17
UPGRADE
Target $78
BOFA
Neutral
PerkinElmer upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded PerkinElmer to Neutral and raised its price target to $78 from $70 ahead ot the pending $1.3B Eurolmmun acquisition. De Bruin said PerkinElmer has been pruning non-core and slower businesses and Eurolmmun is a key step in the portfolio transition with its solid and price competitive autoimmune testing business.
09/26/17
GSCO
09/26/17
INITIATION
Target $67
GSCO
Neutral
PerkinElmer assumed with a Neutral at Goldman Sachs
Goldman analyst Patrick Donnelly assumed coverage on PerkinElmer with a Neutral and $67 price target. The analyst expects below peer growth to continue and believes managements operating profit margin goal of 22% by 2020 is aggressive.
09/26/17
SBSH
09/26/17
NO CHANGE
Target $80
SBSH
Buy
PerkinElmer price target raised to $80 from $74 at Citi
Citi analyst Daniel Arias raised his price target for PerkinElmer shares to $80 after hosting meetings with management. The analyst left the meetings more optimistic that the company's ongoing portfolio evolution can drive a "material organic growth inflection." He maintains a Buy rating on PerkinElmer.
01/03/18
EVER
01/03/18
INITIATION
Target $77
EVER
In Line
PerkinElmer initiated with an In Line at Evercore ISI
Evercore ISI analyst Ross Muken initiated PerkinElmer with an In Line rating and $77 price target.

TODAY'S FREE FLY STORIES

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSB

GlobalSCAPE

$4.55

-0.02 (-0.44%)

17:22
11/16/18
11/16
17:22
11/16/18
17:22
Syndicate
Breaking Syndicate news story on GlobalSCAPE »

GlobalSCAPE files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQIX

Equinix

$388.18

2.67 (0.69%)

17:19
11/16/18
11/16
17:19
11/16/18
17:19
Hot Stocks
Equinix's Lee sells 2,792 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

LMT

Lockheed Martin

$301.06

-4.42 (-1.45%)

17:17
11/16/18
11/16
17:17
11/16/18
17:17
Hot Stocks
Lockheed Martin awarded $282.09M Naval Sea Systems Command contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$2.56

0.045 (1.79%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Hot Stocks
Teligent receives notification of deficiency from Nasdaq »

Teligent said that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$1.82

0.07 (4.00%)

17:16
11/16/18
11/16
17:16
11/16/18
17:16
Syndicate
Breaking Syndicate news story on Staffing 360 Solutions »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

IMMR

Immersion

$9.56

-0.14 (-1.44%)

17:12
11/16/18
11/16
17:12
11/16/18
17:12
Hot Stocks
Breaking Hot Stocks news story on Immersion »

Man Group reports 4.84%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$11.95

0.74 (6.60%)

17:10
11/16/18
11/16
17:10
11/16/18
17:10
Hot Stocks
Breaking Hot Stocks news story on Athenex »

Perceptive Advisors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 02

    Dec

TSRO

Tesaro

$34.96

8.39 (31.58%)

17:08
11/16/18
11/16
17:08
11/16/18
17:08
Recommendations
Tesaro analyst commentary at Piper Jaffray »

Piper Jaffray says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

EEI

Ecology & Environment

$10.50

-2 (-16.00%)

17:05
11/16/18
11/16
17:05
11/16/18
17:05
Hot Stocks
Ecology & Environment receives noncompliance notice from Nasdaq »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEE

Ameren

$69.29

0.01 (0.01%)

16:58
11/16/18
11/16
16:58
11/16/18
16:58
Hot Stocks
Ameren exec Nelson sells $690,000 worth of common shares »

Ameren SVP, general…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQS

Equus II Inc

$1.86

(0.00%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Equus II Inc reports net assets of $46.6M as of September 30 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAPO

Vapotherm

$17.10

-0.42 (-2.40%)

16:56
11/16/18
11/16
16:56
11/16/18
16:56
Hot Stocks
Breaking Hot Stocks news story on Vapotherm »

Redmile Group reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

COTY

Coty

$9.09

0.39 (4.48%)

16:55
11/16/18
11/16
16:55
11/16/18
16:55
Hot Stocks
Coty CEO acquires 2.3M common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

NVS

Novartis

$87.74

0.52 (0.60%)

16:54
11/16/18
11/16
16:54
11/16/18
16:54
Upgrade
Novartis rating change at Goldman Sachs »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.